Reference : Actualités thérapeutiques en oncologie sénologique: place actuelle et perspectives des t...
Scientific journals : Article
Human health sciences : Hematology
http://hdl.handle.net/2268/10061
Actualités thérapeutiques en oncologie sénologique: place actuelle et perspectives des traitements cibles
French
[en] Targeted Therapies in Breast Cancer: Current Status and Perspectives
Jerusalem, Guy mailto [Centre Hospitalier Universitaire de Liège - CHU > > Oncologie médicale >]
Rorive, Andrée [Université de Liège - ULg > Département des sciences cliniques > Hématologie - Oncologie médicale]
Gennigens, Christine mailto [Centre Hospitalier Universitaire de Liège - CHU > > Oncologie médicale >]
Sautois, Brieuc mailto [Centre Hospitalier Universitaire de Liège - CHU > > Oncologie médicale >]
Mievis, C. [> > > >]
Fillet, Georges mailto [Université de Liège - ULg > Département des sciences cliniques > Hématologie - Oncologie médicale]
2007
Revue Médicale de Liège
62 Spec No
2-5
Yes (verified by ORBi)
0370-629X
[en] Bevacizumab ; Breast cancer ; Targeted treatments ; Trastuzumab
[en] The introduction of targeted therapies has largely modified the treatment strategies in oncology. Two targets are currently used for defining the systemic treatment of breast cancer: hormone receptors and HER2 overexpression. Trastuzumab, a monoclonal antibody, is the only registered antiHER2 treatment in Belgium. The association of trastuzumab with chemotherapy is now the recommended adjuvant treatment for early breast cancer overexpressing HER2. Other antiHER2 medications are available and some will probably be registered soon. Angiogenesis is another potential target for improving the treatment results. The CHU Liege, as a reference center for the systemic treatment of solid tumors, participates in many international trials in order to validate these new approaches. The highest quality of care is required to be in compliance with the conduct of these clinical trials. Another benefit for the patient is the easy access to last generation medical treatments, generally not accessible in our health care system in Belgium outside of clinical trials.
http://hdl.handle.net/2268/10061

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
232.pdfPublisher postprint300.14 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.